Literature DB >> 20212336

Antimicrobial susceptibility of Salmonella Typhi in India.

Kavita Nagshetty1, Shivannavar T Channappa, Subhashchandra M Gaddad.   

Abstract

BACKGROUND: Typhoid fever continues to remain a major public health problem, especially in regions such as Gulbarga, due to poor sanitation and personal hygiene. Gulbarga region is often prone to enteric fever outbreaks and is an endemic region of typhoid fever. Enteric fever caused by Salmonella Typhi has not been adequately explored in this region.
METHODOLOGY: A total of 95 isolates of S. Typhi collected from different clinical and environmental sources were tested for antimicrobial susceptibility according to the CLSI guidelines. MIC of resistant isolates to various antibiotics was performed by agar dilution method.
RESULTS: Of the total isolates studied, 10% were found to be multidrug resistant (MDR) (defined as resistance to ampicillin, chloramphenicol and co-trimoxazole). There was a decrease in the susceptibility to ciprofloxacin of S. Typhi with MIC showing an upward trend (0.125-4 microg/mL). Concurrently, there has been an increase in the number of isolates sensitive to all antibiotics except nalidixic acid.
CONCLUSION: MDR S. Typhi continues to be an important public health issue in Gulbarga. Presence of quinolone resistance and associated low-level ciprofloxacin resistance is a concern and requires further study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20212336     DOI: 10.3855/jidc.109

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  22 in total

1.  Antibiogram of Salmonella Isolates: Time to Consider Antibiotic Salvage.

Authors:  R Sharvani; D K Dayanand; Poornima Shenoy; Pooja Sarmah
Journal:  J Clin Diagn Res       Date:  2016-05-01

2.  Increasing antimicrobial resistance and narrowing therapeutics in typhoidal salmonellae.

Authors:  Jaspal Kaurthe
Journal:  J Clin Diagn Res       Date:  2013-03-01

3.  A cross sectional study on antibiotic resistance pattern of Salmonella typhi clinical isolates from Bangladesh.

Authors:  Adnan Mannan; Mohammad Shohel; Sultana Rajia; Niaz Uddin Mahmud; Sanjana Kabir; Imtiaj Hasan
Journal:  Asian Pac J Trop Biomed       Date:  2014-04

4.  Revised Ciprofloxacin Breakpoints for Salmonella: Is it Time to Write an Obituary?

Authors:  Revathy Girish; Anil Kumar; Sadia Khan; Kavitha R Dinesh; Shamsul Karim
Journal:  J Clin Diagn Res       Date:  2013-11-10

5.  Trends in the antibiotic resistance patterns of enteric Fever isolates - a three year report from a tertiary care centre.

Authors:  Varsha Gupta; Nidhi Singla; Neha Bansal; Neelam Kaistha; Jagdish Chander
Journal:  Malays J Med Sci       Date:  2013-07

6.  Antibiogram Profile of Salmonella enterica Serovar Typhi in India - A Two Year Study.

Authors:  Yashwant Kumar; Anshu Sharma; Kavaratty Raju Mani
Journal:  Trop Life Sci Res       Date:  2013-08

7.  Blood culture isolates and antibiogram of Salmonella: Experience of a tertiary care hospital.

Authors:  Lavan Singh; M P Cariappa
Journal:  Med J Armed Forces India       Date:  2015-09-04

8.  Emergence of a globally dominant IncHI1 plasmid type associated with multiple drug resistant typhoid.

Authors:  Kathryn E Holt; Minh Duy Phan; Stephen Baker; Pham Thanh Duy; Tran Vu Thieu Nga; Satheesh Nair; A Keith Turner; Ciara Walsh; Séamus Fanning; Sinéad Farrell-Ward; Shanta Dutta; Sam Kariuki; François-Xavier Weill; Julian Parkhill; Gordon Dougan; John Wain
Journal:  PLoS Negl Trop Dis       Date:  2011-07-19

9.  Cholestatic hepatitis in a patient with typhoid fever - a case report.

Authors:  Eranda C Ratnayake; Chrishan Shivanthan; Bandula C Wijesiriwardena
Journal:  Ann Clin Microbiol Antimicrob       Date:  2011-10-08       Impact factor: 3.944

10.  Antimicrobial susceptibility of Salmonella enterica serovars in a tertiary care hospital in southern India.

Authors:  Ashwini Choudhary; Ram Gopalakrishnan; P Senthur Nambi; V Ramasubramanian; K Abdul Ghafur; M A Thirunarayan
Journal:  Indian J Med Res       Date:  2013-04       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.